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Abstract
Introduction A hallmark of pediatric low-grade glioma (pLGG) is aberrant signaling of the mitogen activated protein kinase 
(MAPK) pathway. Hence, inhibition of MAPK signaling using small molecule inhibitors such as MEK inhibitors (MEKi) 
may be a promising strategy.
Methods In this multi-center retrospective centrally reviewed study, we analyzed 18 patients treated with the MEKi trametinib 
for progressive pLGG as an individual treatment decision between 2015 and 2019. We have investigated radiological response 
as per central radiology review, molecular classification and investigator observed toxicity.
Results We observed 6 partial responses (PR), 2 minor responses (MR), and 10 stable diseases (SD) as best overall responses. 
Disease control rate (DCR) was 100% under therapy. Responses were observed in KIAA1549:BRAF- as well as neurofi-
bromatosis type 1 (NF1)-driven tumors. Median treatment time was 12.5 months (range: 2 to 27 months). Progressive disease 
was observed in three patients after cessation of trametinib treatment within a median time of 3 (2–4) months. Therapy related 
adverse events occurred in 16/18 patients (89%). Eight of 18 patients (44%) experienced severe adverse events (CTCAE III 
and/or IV; most commonly skin rash and paronychia) requiring dose reduction in 6/18 patients (33%), and discontinuation 
of treatment in 2/18 patients (11%).
Conclusions Trametinib was an active and feasible treatment for progressive pLGG leading to disease control in all patients. 
However, treatment related toxicity interfered with treatment in individual patients, and disease control after MEKi with-
drawal was not sustained in a fraction of patients. Our data support in-class efficacy of MEKi in pLGGs and necessity for 
upfront randomized testing of trametinib against current standard chemotherapy regimens.
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Introduction
Low-grade gliomas (pLGG) are the most common brain 
tumors in children and account for about 30% of all pedi-
atric brain tumors [1, 2]. Standard of care (SOC) treat-
ment options such as surgery, followed by chemotherapy 
and occasionally radiotherapy (RT) where indicated, have 
been shown to be effective, leading to 10-year overall sur-
vival (OS) and event-free survival (EFS) of 94% and 44%, 
respectively [3]. Chemotherapy is currently recommended 
as first-line, nonsurgical treatment for most patients [3, 4]. 
Although the disease control rate is excellent (> 90%) for 
all chemotherapy regimens, up to 80% of incompletely 
resected tumors progress and require one or more lines of 
adjuvant therapy. Many patients suffer from extensive tumor 
and treatment related morbidity, e.g. visual function loss, 
motor deficits, deafness, developmental delay, vasculopathy, 
and hypopituitarism [5]. Endocrinopathies, developmental 
abnormalities, and neurocognitive dysfunction are com-
mon late effects after RT [6, 7], and are more pronounced in 
younger children and patients with neurofibromatosis type 1 
(NF1), who are specifically at risk for RT-induced vascular 
malformations [8] and secondary malignancies [9]. It is cur-
rently recommended to avoid or at least defer RT by repeated 
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lines of chemotherapy [10], especially in younger patients 
and patients with NF1. New tailored therapy approaches are 
needed to improve the long-term outcome of pLGG-patients 
and reduce therapy- and disease-related morbidity.
The majority of pLGG show oncogenic activation of the 
mitogen activated protein kinase (MAPK) signaling pathway 
[11–13]. Pilocytic astrocytoma (PA) is the most frequent 
subgroup of pLGG, accounting for about half of all pLGG 
cases [2], with nearly 100% of PAs harboring an activating 
alteration of the MAPK pathway [14]. The most frequent 
aberration is the KIAA1549:BRAF-fusion, beside less fre-
quent alterations such as other BRAF fusions, BRAF muta-
tions, FGFR1 mutations, NF1 mutations, KRAS mutations 
and PTPN11 mutations or NTRK2 fusions [12, 14]. The 
universal activation of the MAPK pathway makes pLGGs 
uniquely suited for targeted treatment approaches. Pre-clini-
cal data points to robust inhibition of the MAPK pathway by 
MEK inhibitors (MEKi) such as selumetinib and trametinib 
in pLGG cells with KIAA1549:BRAF-fusion or BRAF 
V600E mutation [15, 16]. Selumetinib has been studied in 
a series of clinical trials: 20% of patients with recurrent or 
progressive pLGG showed sustained partial response in a 
phase I clinical trial [17] and 36–40% of progressive pLGG 
patients experienced a sustained partial response in a phase 
II trial [18]. Selumetinib also showed significant activity in 
NF1-associated plexiform neurofibromas (PNF), which are 
otherwise resistant to systemic therapy, leading to the first 
approval of a MEKi in a specific pediatric indication [19].
Trametinib is currently being tested in phase I/II clini-
cal trials (NCT02124772) and first limited data is avail-
able in abstract format for patients with BRAF fusions 
[20]. The published data on the activity of trametinib 
in pLGG is derived from case series [21–24]. Two case 
series reported on two and six progressive PA patients with 
KIAA1549:BRAF-fusion [21, 23], with two partial responses 
(PR) in one study [23], and two partial responses (PR), three 
minor responses (MR) and one progressive disease (PD) in 
the second [21]. The third case series [24] reports on 14 
low- and high-grade pediatric MAPK-altered brain tumors 
of different histologies (11 low-grade and 3 high-grade 
tumors) treated with trametinib alone or in combination. 
Eight of the 11 patients with low-grade tumors received 
trametinib monotherapy, of which four had a BRAF-fusion, 
one had a BRAF V600E mutation, one an NF1 alteration and 
two no detected MAPK alteration. In these seven tumors 
treated with trametinib monotherapy, best responses were 
three PRs, two PD, one SD, and two missing responses 
due to early treatment stop because of toxicity. The most 
recently published case series [22] reported on eleven 
pLGG patients treated with trametinib, four of which had a 
KIAA1549:BRAF-fusion, four an NF1 mutation, one had an 
FGFR mutation and one had a CDKN2A loss. The underly-
ing molecular alteration was unknown in one patient. The 
authors reported on two PRs, two MRs and six SDs under 
trametinib treatment.
Several clinical trials will evaluate trametinib prospec-
tively in pLGGs. The TRAM-01 trial [25] is a phase II mul-
ticentric open-label basket trial including four groups (NF1 
LGG, NF1 PNF, BRAF-fusion LGG, other MAPK-acitvated 
glioma). The upcoming LOGGIC Europe trial is the first 
prospective randomized clinical trial to compare trametinib 
to the SOC carboplatin/vincristine and to vinblastine mono-
therapy in newly diagnosed pediatric LGG patients.
Here we report the results of a retrospective centrally 
reviewed multi-center study of the activity and toxicity of 
trametinib in the largest pLGG series to date, consisting of 
18 patients with molecularly characterized pLGGs, eight 
with NF1-related and ten with sporadic BRAF-fusion- posi-
tive, BRAF V600E-positive or FGFR-mutated pLGGs.
Methods
A retrospective multi-center analysis of pLGG patients 
treated with trametinib in “off-label-use” in eight centers in 
Germany between 2015 and 2019 was performed. Consent 
for data collection was obtained by inclusion of patients in 
clinical and diagnostic studies, either the SIOP-LGG-2004 
trial (NCT00276640), the LGG registry or PTT2.0 (NCT-
2016-0414; DRKS00011707). Participation in SIOP-
LGG-2004 trial and registry allowed for retrospective tissue 
and MRI analyses beyond the completion of trial-required 
components. Molecular work-up of the tumors in cases 
with available material had either already been done by the 
treating centers or via PTT2.0 or was performed retrospec-
tively on archived tissue material. Molecular classification 
was done by DNA methylation array [26]. NF1 alterations 
were detected by sequencing of the NF1 locus or gene panel 
sequencing [27]. BRAF and FGFR1 mutations were detected 
by gene panel sequencing [27]. BRAF-fusions were detected 
by FISH, gene panel sequencing, copy number plot analysis, 
or targeted PCR. Grading of therapy related adverse events 
(AE) was retrospectively done according to Common Ter-
minology Criteria for Adverse Events (CTCAE) V5.0 [28]. 
Response assessment by MRI to trametinib treatment was 
retrospectively centrally reviewed at the Neuroradiological 
Reference Center for HIT-Studies in Würzburg, Germany, 
and evaluated in accordance with the SIOP-LGG study 
guidelines described in the SIOPE-BTG and GPOH Guide-
lines for Diagnosis and Treatment of Children and Adoles-
cents with Low Grade Glioma [4] and the more recently 
published RAPNO criteria for LGG [29]. The tumor vol-
ume was calculated using the (ellipsoid volume) formula ½ 
(AxBxC), where A, B and C are the maximum dimensions 
in the standard planes.
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All sequences available were used for evaluation. For 
measurement the sequence best depicting the tumor extent 
was used, i.e. primarily T2 or T2 FLAIR in two planes in 
case of partly or non-enhancing tumors and T1 images post 
contrast only for completely enhancing tumors. Due to the 
retrospective nature of the study, not all MRIs were con-
ducted according to the same standards including standard 
sequences and forced deviations from RAPNO recommen-
dations in cases where tumors had to be measured using 
T1 images post contrast images. Responses were calculated 
in relation to pre-treatment baseline MRIs. The response 
criteria were defined as follows: complete response (CR) 
defined as no evidence of residual or recurrent tumor or dis-
semination; partial response (PR) defined as reduction of 
tumor volume ≥ 50% and no new lesions; minor response 
(MR) defined as reduction in tumor volume between 25 and 
50% without new lesions; stable disease (SD) defined as 
change in tumor volume between +25% and − 25% without 
new lesions, and progressive disease (PD) defined as ≥ 25% 
increase in tumor size or appearance of new lesions. Tumors 
that were not able to be captured by the ellipsoid, as it was 
the case for most opticohypothalamic tumors, were rated as 
non measureable but eligible according to the LGG Guide-
line [4] and RAPNO LGG [29]. The volume had to be esti-
mated to the best knowledge and experience of the reference 
center. This estimation has been correlated with calculation 
of measureable representative parts of the tumor. Disease 
control rate (DCR) was defined as the sum of CR, PR, MR 
and SD. Response of NF1-related non-pLGG lesions (neu-
rofibromas (NFs) or PNFs), if present, to trametinib treat-
ment was documented but not centrally reviewed. Volume 
of PNFs in one NF1 patient (patient 6) was determined by 
MedX software (v3.42). MedX utilizes a heuristic-based 
semi-automated method for segmentation and measurement 
and assessment has been proven as sensitive and reproduc-
ible, yielding results similar to manual tracings of tumor 
margins [30].
Results
Patient characteristics and prior treatments
Patients’ characteristics are shown in detail in Table 1. 
Median age at diagnosis was 2.1 years (range: 0.5–9.9). 
The diagnostic and molecular work-up is shown in Fig. 1a 
and diagnostic and molecular data is summarized in 
Fig. 1b. Ten of 18 (56%) patients had sporadic pLGG and 
8/18 (44%) patients had NF1-related pLGG. Histology 
was available for 14/18 (78%) patients while 4/18 (22%) 
patients did not undergo surgery and diagnosis was made 
based on clinical criteria of NF1 and typical radiology fea-
tures by central reference review. Among the patients with 
available histology, 13 were diagnosed with PA and one 
was diagnosed with diffuse astrocytoma (DA). DNA meth-
ylation data was already available for 8/18 (44%) patients. 
DNA methylation arrays were retrospectively added in 
3/18 (17%) patients (patients 10, 15 and 17) leading to 
11/18 (61%) patients with DNA-methylation data. In total 
7/18 (38%) patients were classified as low-grade gliomas 
by methylation array (full match). 3/18 (17%) showed the 
highest similarity to LGG according to DNA-methylation 
or tSNE clustering although the methylation scores were 
below the cut-off (best match). One tumor could not be 
classified by DNA methylation array (patient 10). Infor-
mation on the underlying MAPK alteration was already 
available for 11/18 (61%) patients and was retrospectively 
detected in 2/18 (11%) patients (patients 15 and 17) lead-
ing to a total of 13/18 (72%) of patients with molecularly 
Table 1  Patients’ characteristics
PA pilocytic astrocytoma, DA diffuse astrocytoma, OPG optico-hypo-
thalamic glioma
Number of patients included, n (%): 18 (100)




Neurofibromatosis type 1, n (%)
 Yes 8 (44)
 No 10 (56)
Tumor localization, n (%)
 OPG 12 (66)
 OPG + brain stem 1 (6)
 Brain stem 4 (22)
 Cranio-cervical 1 (6)




 > 1 partial resection 3 (17)
 1 partial resection 7 (38)
 Biopsy 3 (17)
 Cyst fenestration 1 (6)
 No surgery 4 (22)
Number of prior chemotherapy lines, n (%):
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detected MAPK alteration. Alterations detected included 
8 KIAA1549:BRAF-fusions, three NF1 alterations, one 
BRAF V600E mutation and one FGFR1 K654Q mutation. 
Of note, molecular NF1 testing was performed in blood 
and tumor in two patients (patient 2: p.514_514del, and 
patient 18: p.888fs, both detected by gene panel sequenc-
ing) and only in blood in one patient (patient 4: p.1153fs 
detected by targeted sequencing of the NF1 gene includ-
ing exon-flanking intronic regions). The remaining 5/18 
(33%) patients, who either did not undergo surgery or did 
not have remaining material, all had a clinical diagnosis of 
NF1 and an NF1 alteration could be assumed. 
Sixteen of 18 (89%) patients had received prior treatment 
for pLGG including surgery, chemotherapy, radiotherapy, or 
combinations thereof. Ten of 18 (55%) patients had at least 
one tumor volume reductive surgery. Sixteen of 18 (89%) 
patients had at least one prior line of chemotherapy and 
7/18 (38%) had more than three chemotherapy lines (range: 
four to ten). Regimens used included carboplatin/vincris-
tine (according to the SIOP-LGG 2004 protocol), vinblastine 
monotherapy, and less common protocols. One patient had 
received proton beam radiotherapy and one gamma knife 
radiosurgery. Two NF1 patients had no prior pLGG-related 
treatment.
Fig. 1  Overview of diagnos-
tic and molecular work-up a 
Diagnostic and molecular work-
flow b Graphical summary of 
diagnostic and molecular fea-
tures for each patient included. 
PA pilocytic astrocytoma, 
DA diffuse astrocytoma, PF 
PA subclass posterior fossa 
pilocytic astrocytoma, Midline 
PA subclass midline pilocytic 
astrocytoma; “full match”, suc-
cessful methylation classifica-
tion; “best match”, methylation 
classification score below cut-
off but highest similarity to the 
indicated methylation class/sub-
class; Not classified, no match 
with any of the methylation 
reference classes; n/a not appli-
cable, testing not performed 
because no tumor material was 
available. Of note, molecular 
NF1 testing was performed in 
blood and tumor in two patients 
(patient 2 and 18) and only in 
blood in one patient (patient 4)
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Targeted treatment with trametinib and response 
to treatment
Eighteen pLGG patients received trametinib for their pro-
gressive tumor. All 18 patients presented with an indication 
to therapy due to MRI-morphological tumor progression 
when trametinib therapy was initiated and either had devel-
oped new neurological symptoms or were at risk of devel-
oping tumor related symptoms due to the location of their 
tumor. Targeted therapy was initiated after failure of prior 
SOC treatments in 16/18 (89%) patients, while two patients 
with NF1-associated pLGG 2/18 (11%) and clinical signifi-
cant PNFs had not received prior SOC. Details on trametinib 
treatment and treatment response are summarized in Table 2. 
All tumors were radiologically evaluable but most tumors 
were not measurable due to irregular shape precluding exact 
volumetry. Response was categorized in response categories 
(SD, MR, PR, CR). Best overall responses were observed 
after a median treatment time of 4 (range: 1–19) months 
and included 6 PR, 2 MR and 10 SD (Fig. 2a, b). MR and 
PR was observed in KIAA1549:BRAF-fusion- and NF1-
driven pLGG (Fig. 2b). Disease control rate (DCR) during 
treatment with trametinib was 100%. One PD was observed 
retrospectively by central radiological review after 3 months 
of trametinib treatment (patient 3). The increase in volume 
was slightly above + 25% according to central review and 
had not been assessed as PD by local radiology at the time 
of treatment. Therefore, treatment was continued and the 
patient then showed SD compared to baseline tumor volume 
assessment in the further course. The median duration of 
treatment was longer in the group of patients with either MR 
or PR (median 16.5; range 11–27 months) as compared to 
patients with SD as best overall response (9.5; 2–21 months). 
Patients with MR or PR had lower numbers of prior chemo-
therapy lines (median: 1.5; range: 0–5 months) compared 
to patients with SD (5; 1–10). No differences in response 
based on age at trametinib onset, localization of the tumor, 
histology or underlying molecular alteration were observed. 
Follow‑up after end of treatment
Ten of 18 (56%) patients had stopped trametinib therapy at 
the end of data collection, and 8/18 (44%) were still (n = 7) 
or again (n = 1; re-initiation due to progression after EOT) on 
treatment (Table 2; Fig. 2a). One patient stopped trametinib 
just before the end of data collection and no follow-up (FU) 
data was available (patient 2). The median FU time of the 
9/10 patients after EOT was seven (range 1–33) months. One 
patient (patient 17, clinical PD) died of the disease 1 month 
after EOT, accompanied by multiple severe complications 
related to either the disease (hyponatremia) or prior therapies 
(oto-, hemato-, and cardiac toxicities; infection of intraven-
tricular reservoir causing severe meningoencephalitis). One 
patient (patient 14) received vinblastine 7 months after EOT 
due to disease progression and another patient (patient 18) 
received bevacizumab 1 month after EOT due to increase in 
tumor size (not PD). Six patients had no further treatment. 
One sustained PR (31 months after EOT), one sustained MR 
(4 months after EOT), three sustained SD (three, 25 and 
33 months after EOT, respectively) and one PD (patient 8, 
2 months after EOT, without need for treatment due to spon-
taneous stabilization 10 months after EOT) were observed 
during FU. NF1-related non-pLGG tumors (NFs/PNFs) 
Table 2  Treatment with trametinib, response, and follow-up after end 
of treatment
SEM standard error of mean, PR partial response, MR minor 
response, SD stable disease, PD progressive disease, EOT end of 
treatment, N/A not applicable
Median age at trametinib onset, years (range) 8.2 (3.5–17.3)
Status before treatment, n (%)
 Progressing tumor 14 (78)
 Progressing tumor with visual impairment 2 (11)
 Progressing tumor with worsened neurological 
symptoms
2 (11)
Mean trametinib dose, mg/kg*day (SEM) 0.03 (± 0.009)
Median treatment time, months (range) 12.5 (2–27)





Disease control rate, n (%) 18 (100)
Time to best overall response, months (range) 4 (1–19)
Treatment status, n (%)
 Ongoing 7 (38)
 Stopped 10 (56)
 Re-initiated and ongoing after end of treatment 1 (6)
Reason for discontinuation of trametinib, n (%)
 Sustained response/SD 2 (11)
 Planned EOT/decision of treating physician 2 (11)
 Treatment related side effects 2 (11)
 Further loss of vision 1 (6)
 Increasing tumor volume 2 (11)
 N/A 1 (6)
Last status after EOT (10 patients; median follow up 7 (1–33) 
months), n (%)
 PR, no further treatment 1 (6)
 MR, no further treatment 1 (6)
 SD, no further treatment 3 (17)
 PD, no further treatment 1 (6)
 Progression, different treatment initiated 1 (6)
 Increase in tumor size, different treatment initiated 1 (6)
 Death 1 (6)
 N/A 1 (6)
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of three NF1 patients showed no change in tumor volume 
during trametinib treatment (SD; not centrally reviewed) 
and volumetry of PNFs in another NF1 patient (patient 6) 
showed a reduction of tumor volume by 26% under treatment 
(not shown).
Progression after trametinib withdrawal
Three of 11 (27%) patients (patients 1, 8 and 14; Fig. 2a) 
who stopped trametinib treatment showed progression after 
the end of treatment within two to four months. One tumor 
(patient 1; Fig. 2a) had initially shown PR during the first 
round of treatment, and stabilization (SD) was observed 
after re-initiation of trametinib treatment upon PD.
Trametinib‑related adverse events
Sixteen of 18 (89%) experienced at least one trametinib-related 
AE. The most frequent AEs were skin-related, with macu-
lopapular rash, paronychia, acneiform rash and xerodermia 
being the most commonly reported AEs (Table 3). At least 
one CTCAE v5.0 grade III or IV AE was reported in 8/18 
(44%) patients. This included acneiform rash (17%), erysipelas 
(11%), maculopapular rash (11%), paronychia (6%), eczema 
(6%), dermatitis bullosa (6%) and pancreatitis (6%). Of note, 
one patient experienced a pneumococcal meningitis. However, 
Fig. 2  Response to trametinib 
treatment a Swimmer plot 
demonstrating the duration of 
exposure to trametinib analyzed 
by centrally reviewed best over-
all response. b Best responses 
depicted in categories (PD 
progressive disease >  + 25% 
size change, SD stable disease, 
between + 25% and − 25% size 
change; MR minor response, 
between > − 25 and < − 50% 
size change, PR partial 
response, > 50% size change, 
CR complete response, − 100% 
size change) for each individual 
patient in the context of pLGG 
type and underlying molecular 
alteration. Of note, molecular 
NF1 testing was performed in 
blood and tumor in two patients 
(patient 2 and 18) and only in 
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the relatedness to trametinib treatment remained uncertain 
since this has not been reported as trametinib-associated AE 
in larger adult trametinib studies. Most AEs were well man-
ageable by supportive care and/or short treatment interrup-
tions. Dose limiting toxicities occurred in 6/18 (33%) patients 
and prompted dose reduction to 33–75% of the starting dose. 
Based on our limited data there was no correlation between 
dose reduction and treatment response. The severity of the 
AEs resulted in discontinuation of treatment in 2/18 (11%) 
patients (acneiform rash in both cases). No treatment related 
death was observed. AEs were gathered from medical records 
and may have been underestimated when compared to a pro-
spective clinical trial.
Discussion
While safety and efficacy of the MEKi selumetinib in the 
treatment of pLGG has been well documented [17, 18], 
there is still only limited data on the MEKi trametinib in 
the context of pLGG treatment. Selumetinib was shown 
to be active in different genetic backgrounds including 
KIAA1549:BRAF fusions, BRAF V600E mutation and NF1 
mutations in clinical phase 1 and 2 trials [17, 18]. How-
ever, activity of trametinib in pLGG has only been described 
in small retrospective case series and case reports [21–24, 
31]. We here report on 18 patients with KIAA1549:BRAF-, 
BRAF V600E-, FGFR1- or NF1-driven progressive pLGG 
treated with the MEKi trametinib between 2015 and 2019. 
Of note, our cohort was mainly comprised of patients with 
optico-hypothalamic tumors and the median age at diagnosis 
was low (2.1 years) compared to the median age at diagnosis 
for all pLGG (7.6 years), thus representing a clinically rather 
high risk LGG cohort [32]. Two NF1 patients (patients 6 
and 11) with additional clinical significant, unresectable 
plexiform neurofibroma (PNF) received first line trametinib 
treatment outside of a clinical trial (not available). A PR of 
the pLGG as well as size reduction of their PNF was seen 
for both patient 6 (PNF size change: -26%) and 11 (no exact 
PNF volumetry). MEKi are indeed the only proven effec-
tive treatment for PNFs in NF1 patients [33], and have in 
particular been shown to be efficacious in NF1-related optic 
pathway gliomas in a phase 2 study [18]. The response rates 
of NF1-related pLGG treated with selumetinib [18] appear 
to be similar to the response rates of NF1-related pLGG 
treated with chemotherapy [34]. Non-approved drugs should 
not be used outside clinical trials, but first line MEKi treat-
ment could be justified in this particular patient cohort and 
clearly underscores the urgent need for recruiting clinical 
trials. Disease control rate was 18/18 (100%) under treat-
ment, and 6/18 (33%) patients showed PR as best overall 
response. PR was observed in both, KIAA1549:BRAF- and 
NF1-driven tumors. The responses observed here were com-
parable to published data on pLGG patients treated with 
selumetinib where PR was documented as best response 
in 36%-40% of relapsed pLGG patients [18]. Of note, our 
study differed in terms of response-assessment in some 
aspects. This was due to a high rate of evaluable but non-
measurable tumors precluding exact volumetry as well as 
to the retrospective nature of our study where not all MRIs 
were conducted according to the same standards in regard 
to both imaging sequences and timepoints. These factors 
have to be taken into account when comparing our data to 
response data from other studies. Unlike for selumetinib 
(reported median time to partial response: 7.54 months [18]) 
no phase II data on the time to best response after initiation 
of trametinib treatment in pLGG patients is available. The 
median time to best response in our cohort was shorter 
(median: 4, range: 1–19 months) compared to the report of 
Manoharan et al. (9.8; 3.8–22 months) [22]. However, the 
median time of treatment was shorter (12.5; 2–27 months) in 
our cohort compared to the study of Manoharan et.al. (19.2; 
3.8–29.8 months). Since best responses to trametinib can 
Table 3  Treatment related adverse events
CTCAE common terminology criteria for adverse events
All CTCAE grades CTCAE 
grade III/
IV
Patients with adverse events, n (%) 16 (89) 8 (44)
Treatment related adverse events, n (%)
 Rash maculopapular 7 (38) 2 (11)
 Paronychia 7 (38) 1 (6)
 Rash acneiform 5 (28) 3 (17)
 Xerodermia 4 (22) 0 (0)
 Diarrhea 2 (11) 0 (0)
 Dizziness 2 (11) 0 (0)
 Eczema 2 (11) 1 (6)
 Erysipelas 2 (11) 2 (11)
 Fatigue 2 (11) 0 (0)
 Oral mucositis 2 (11) 0 (0)
 Pruritus 2 (11) 0 (0)
 Abdominal pain 1 (6) 0 (0)
 Bilirubin elevation 1 (6) 0 (0)
 Constipation 1 (6) 0 (0)
 Dermatitis bullosa 1 (6) 1 (6)
 Infection without causative agent 1 (6) 0 (0)
 Left ventricular dysfunction 1 (6) 0 (0)
 Pancreatitis 1 (6) 1 (6)
 Pneumococcal meningitis 1 (6) 1 (6)
 Sinus bradycardia 1 (6) 0 (0)
Dose limiting toxicity, n (%) 6 (33)
Dose reduction, n (%) 6 (33)
Adverse event related discontinua-
tion of treatment, n (%)
2 (11)
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occur after as much as 22 months after initiation of treatment 
[22], the comparably low median total treatment duration of 
our cohort may underestimate response rates as well as the 
time to best response. Moreover, in our cohort duration of 
treatment was longer in the group of patients who experi-
enced at least MR (16.5 (range 11–27) months) as compared 
to patients with SD as best overall response (median 9.5 
(range: 2–21) months), indicating that treatment duration 
could be a parameter influencing response rates. No patient 
in our cohort showed CR during/after trametinib treatment. 
This observation is compatible with most other reports on 
MEKi showing that CR mostly cannot be achieved in pro-
gressive pLGG by MEKi treatment alone [18, 21, 23, 31, 
35]. CR-rates after MEKi treatment in the setting of pro-
gressive pLGG are by that equally low as in primary pLGG 
treated with conventional chemotherapy, where about only 
1–2% of patients experience CR [36]. The low rates of CR 
indicate that parts of the tumor may not be targetable by 
the MEKi treatment alone, just as is the case with cytotoxic 
conventional chemotherapy. It is conceivable that this non-
responding compartment, possibly quiescent through OIS 
and SASP [15, 37], is the source of the progression observed 
in some patients after EOT with targeted treatments. Sup-
plementary strategies will therefore be needed to implement 
additional therapeutic regimens to improve treatment out-
come and PFS of these patients. These could include e.g. 
the inhibition of other MAPK-related survival pathways like 
AKT/mTOR [38], or the use of senolytic drugs [37], both 
of which remain to be introduced into the clinical treatment 
of pLGGs.
PD was observed in 3/11 (27%) of the patients who 
stopped trametinib, within 4 months after EOT. The effect 
of rapid pLGG progression after MEKi withdrawal has 
already been described in the phase I clinical selumetinib 
study [17]: 10/39 (26%) patients experienced tumor 
regrowth within 6 months after EOT with selumetinib. 
Interestingly, seven of the ten patients progressing after 
EOT from the selumetinib study were not treated for the 
full planned 26 cycles (~ 25 months) due to toxicity or 
patient/physician preference possibly indicating that total 
treatment time (median of 12.5 months in the present 
cohort) may have an impact on PFS. Of note, re-initiation 
of trametinib treatment in one of the patients from the 
present cohort patients was able to stop progression and 
to induce a second disease stabilization (SD). This indi-
cates that the tumor did not develop a bona fide resist-
ance but retained its susceptibility towards the inhibitor, 
and that re-challenge with the same drug is an option, as 
has been reported for BRAFi [39]. The phenomenon of 
occasional rapid progression after MEKi treatment seems 
to be a class-specific effect, since it was also observed in 
the present study and is thus not restricted to selumetinib. 
This highlights the need for further preclinical work in 
order to define underlying mechanisms (e.g. modulation of 
oncogene-induced senescence, feedback modulations, etc.) 
and the best treatment modalities (treatment time, combi-
nation treatment, etc.) to overcome tumor growth rebound.
The mean dose of trametinib in our cohort was 0.03 mg/
kg*day (± 0.009 mg/kg*day), which is in line with the 
recently published recommended phase II dose for pediat-
ric patients six years of age and older [35]. Therapy related 
side effects occurred in 89% of our patients. This is com-
parable to results from a trametinib phase I clinical trial 
conducted in adult patients with advanced solid tumors, 
in which more than 90% of the trametinib treated patients 
developed toxicities [40]. The most frequent adverse 
events seen in our cohort were paronychia and different 
types of skin rashes, which were previously reports after 
MEKi treatments [17, 18, 35]. Dose limiting toxicities 
were documented in 32–40% of patients in the phase II 
selumetinib trial in pLGG and 3–12% had to discontinue 
treatment due to toxic effects [18]. Comparable to these 
findings, dose limiting adverse events were seen in 6/18 
patients (33%), prompting repetitive treatment interrup-
tions, and termination of treatment in 2/18 patients (11%). 
Similar rates of trametinib discontinuation due to toxic-
ity have been reported in pediatric patients by Paul et al. 
[24]. We therefore conclude that some individual patients 
may display an unacceptable toxicity profile, in particular 
skin toxicity, underscoring the need for early and thorough 
dermatologist support in trametenib-treated children. We 
could not detect a correlation between dose reduction and 
response to therapy. This was also not reported in other 
case series on trametinib treatment of pLGG [21, 22, 24]. 
However, a correlation between dose reduction and change 
in response to therapy needs to be investigated by prospec-
tive trials.
In summary, we can confirm that oral trametinib treat-
ment results in clinically meaningful responses in progres-
sive pLGG patients with either KIAA1549:BRAF-fusion 
or NF1 mutation. This strongly supports the evaluation of 
upfront MEKi treatment in the context of newly diagnosed 
patients with pLGGs within upcoming phase III clinical tri-
als (e.g. the LOGGIC Europe trial).
Based on our data we conclude: (1) trametinib alone is 
probably not sufficient to induce tumor regression in all pro-
gressing patients, and drug combinations/additional targets 
need to be explored. (2) The underlying biological mecha-
nisms behind the rapid progression of tumors in a fraction 
of patients after MEKi treatment need to be understood and 
addressed. (3) Most common adverse events associated with 
trametinib treatment are related to skin toxicity, requiring 
dose reduction or treatment discontinuation in individual 
cases, and warrant comprehensive skin care as well as early 
dermatologist support in affected children. These aspects 
highlight the need for alternative clinical strategies.
507Journal of Neuro-Oncology (2020) 149:499–510 
1 3
Acknowledgements We gratefully acknowledge the contribution of 
the patients who participated in the study.
Author contributions Conceptualization: TM, FS, OW; Formal analy-
sis and investigation: all authors; Writing—original draft preparation: 
FS, TM; Writing—review and editing: all authors; Supervision: TM.
Funding Open Access funding enabled and organized by Projekt 
DEAL. OW, SMP, DTWJ and TM gratefully acknowledge the sup-
port from The Brain Tumour Charity (TBTC, The Everest Centre for 
Low-Grade Paediatric Brain Tumours; GN-000382). OW, SMP and 
DTWJ gratefully acknowledge the support from the PLGA Fund at 
the Pediatric Brain Tumor Foundation. SMP, DTWJ, FeSa gratefully 
acknowledge the support by the German Childhood Cancer Founda-
tion (Deutsche Kinderkrebsstiftung) for the Molecular Neuropathology 
2.0 (MNP2.0) study. AG thankfully acknowledges the support by the 
German Childhood Cancer Foundation (Deutsche Kinderkrebsstiftung) 
for the German SIOP-LGG-2004 and LGG-registry center in Augsburg 
(grants no. 2004.5, 2007.10, 2010.08). BB and the Neuroradiologi-
cal Reference Center for the HIT-Studies is supported by the German 
Childhood Cancer Foundation (Deutsche Kinderkrebsstiftung). OW 
and TM gratefully acknowledge the support from The Bilger family, 
Verein für krebskranke Kinder Odenwald e.V., Aktion für krebskranke 
Kinder Pfalz e.V. TM is supported by the DKTK German Cancer 
Consortium.
Data availability The datasets generated during and/or analyzed dur-
ing the current study are available from the corresponding author on 
reasonable request.
Compliance with ethical standards 
Conflicts of interest CVT discloses advisory roles for Bayer and 
Novartis. PHD discloses advisory roles for Novartis. OW discloses 
advisory roles for Novartis, Roche, Astra Zeneca, BMS, and Janssen.
Consent to participate Consent for data collection was obtained prior 
to inclusion in the clinical and diagnostic studies mentioned above.
Consent for publication Consent for publication was obtained by inclu-
sion in the clinical and diagnostic studies mentioned above.
Ethical approval Patients were included in clinical and/or diagnostic 
studies, either the SIOP-LGG-2004 trial (NCT00276640), the LGG 
registry or PTT2.0 (NCT-2016-0414; DRKS00011707). Ethics approv-
als of the respective studies apply.
Open Access This article is licensed under a Creative Commons Attri-
bution 4.0 International License, which permits use, sharing, adapta-
tion, distribution and reproduction in any medium or format, as long 
as you give appropriate credit to the original author(s) and the source, 
provide a link to the Creative Commons licence, and indicate if changes 
were made. The images or other third party material in this article are 
included in the article’s Creative Commons licence, unless indicated 
otherwise in a credit line to the material. If material is not included in 
the article’s Creative Commons licence and your intended use is not 
permitted by statutory regulation or exceeds the permitted use, you will 
need to obtain permission directly from the copyright holder. To view a 
copy of this licence, visit http://creat iveco mmons .org/licen ses/by/4.0/.
References
 1. Ostrom QT, Cioffi G, Gittleman H, Patil N, Waite K, Kruchko C, 
Barnholtz-Sloan JS (2019) CBTRUS statistical report: primary 
brain and other central nervous system tumors diagnosed in the 
United States in 2012–2016. Neuro Oncol 21:v1–v100. https ://
doi.org/10.1093/neuon c/noz15 0
 2. Ostrom QT, de Blank PM, Kruchko C, Petersen CM, Liao P, Fin-
lay JL, Stearns DS, Wolff JE, Wolinsky Y, Letterio JJ, Barnholtz-
Sloan JS (2015) Alex’s lemonade stand foundation infant and 
childhood primary brain and central nervous system tumors diag-
nosed in the United States in 2007–2011. Neuro Oncol 16(Suppl 
10):x1–x36. https ://doi.org/10.1093/neuon c/nou32 7
 3. Gnekow AK, Falkenstein F, von Hornstein S, Zwiener I, Berkefeld 
S, Bison B, Warmuth-Metz M, Driever PH, Soerensen N, Kort-
mann RD, Pietsch T, Faldum A (2012) Long-term follow-up of 
the multicenter, multidisciplinary treatment study HIT-LGG-1996 
for low-grade glioma in children and adolescents of the German 
Speaking Society of Pediatric Oncology and Hematology. Neuro 
Oncol 14:1265–1284. https ://doi.org/10.1093/neuon c/nos20 2
 4. Gnekow AK, Kandels D, van Tilburg C, Azizi AA, Opocher E, 
Stokland T, Driever PH, Meeteren A, Thomale UW, Schuhmann 
MU, Czech T, Goodden JR, Warmuth-Metz M, Bison B, Avula 
S, Kortmann RD, Timmermann B, Pietsch T, Witt O (2019) 
SIOP-E-BTG and GPOH guidelines for diagnosis and treatment 
of children and adolescents with low grade glioma. Klin Padiatr 
231:107–135. https ://doi.org/10.1055/a-0889-8256
 5. Armstrong GT, Conklin HM, Huang S, Srivastava D, Sanford R, 
Ellison DW, Merchant TE, Hudson MM, Hoehn ME, Robison 
LL, Gajjar A, Morris EB (2011) Survival and long-term health 
and cognitive outcomes after low-grade glioma. Neuro Oncol 
13:223–234. https ://doi.org/10.1093/neuon c/noq17 8
 6. Kortmann RD, Timmermann B, Taylor RE, Scarzello G, Plass-
wilm L, Paulsen F, Jeremic B, Gnekow AK, Dieckmann K, Kay S, 
Bamberg M (2003) Current and future strategies in radiotherapy 
of childhood low-grade glioma of the brain. Part II: treatment-
related late toxicity. Strahlenther Onkol 179:585–597. https ://doi.
org/10.1007/s0006 6-003-8104-0
 7. Merchant TE, Conklin HM, Wu S, Lustig RH, Xiong X (2009) 
Late effects of conformal radiation therapy for pediatric patients 
with low-grade glioma: prospective evaluation of cognitive, endo-
crine, and hearing deficits. J Clin Oncol 27:3691–3697. https ://
doi.org/10.1200/JCO.2008.21.2738
 8. Grill J, Couanet D, Cappelli C, Habrand JL, Rodriguez D, Sainte-
Rose C, Kalifa C (1999) Radiation-induced cerebral vasculopathy 
in children with neurofibromatosis and optic pathway glioma. Ann 
Neurol 45:393–396
 9. Broniscer A, Baker SJ, West AN, Fraser MM, Proko E, Kocak M, 
Dalton J, Zambetti GP, Ellison DW, Kun LE, Gajjar A, Gilbertson 
RJ, Fuller CE (2007) Clinical and molecular characteristics of 
malignant transformation of low-grade glioma in children. J Clin 
Oncol 25:682–689. https ://doi.org/10.1200/JCO.2006.06.8213
 10. Kortmann RD, Timmermann B, Taylor RE, Scarzello G, Plass-
wilm L, Paulsen F, Jeremic B, Gnekow AK, Dieckmann K, Kay S, 
Bamberg M (2003) Current and future strategies in radiotherapy 
of childhood low-grade glioma of the brain. Part I: Treatment 
modalities of radiation therapy. Strahlenther Onkol 179:509–520
 11. Zhang J, Wu G, Miller CP, Tatevossian RG, Dalton JD, Tang B, 
Orisme W, Punchihewa C, Parker M, Qaddoumi I, Boop FA, Lu 
C, Kandoth C, Ding L, Lee R, Huether R, Chen X, Hedlund E, 
Nagahawatte P, Rusch M, Boggs K, Cheng J, Becksfort J, Ma 
J, Song G, Li Y, Wei L, Wang J, Shurtleff S, Easton J, Zhao D, 
Fulton RS, Fulton LL, Dooling DJ, Vadodaria B, Mulder HL, 
Tang C, Ochoa K, Mullighan CG, Gajjar A, Kriwacki R, Sheer 
D, Gilbertson RJ, Mardis ER, Wilson RK, Downing JR, Baker SJ, 
508 Journal of Neuro-Oncology (2020) 149:499–510
1 3
Ellison DW, St. Jude Children’s Research Hospital-Washington 
University Pediatric Cancer Genome P (2013) Whole-genome 
sequencing identifies genetic alterations in pediatric low-grade 
gliomas. Nat Genet 45:602–612. https ://doi.org/10.1038/ng.2611
 12. Jones DT, Kocialkowski S, Liu L, Pearson DM, Backlund LM, 
Ichimura K, Collins VP (2008) Tandem duplication producing 
a novel oncogenic BRAF fusion gene defines the majority of 
pilocytic astrocytomas. Cancer Res 68:8673–8677. https ://doi.
org/10.1158/0008-5472.CAN-08-2097
 13. Ryall S, Zapotocky M, Fukuoka K, Nobre L, Guerreiro Stucklin 
A, Bennett J, Siddaway R, Li C, Pajovic S, Arnoldo A, Kowalski 
PE, Johnson M, Sheth J, Lassaletta A, Tatevossian RG, Orisme 
W, Qaddoumi I, Surrey LF, Li MM, Waanders AJ, Gilheeney 
S, Rosenblum M, Bale T, Tsang DS, Laperriere N, Kulkarni A, 
Ibrahim GM, Drake J, Dirks P, Taylor MD, Rutka JT, Laughlin 
S, Shroff M, Shago M, Hazrati LN, D’Arcy C, Ramaswamy V, 
Bartels U, Huang A, Bouffet E, Karajannis MA, Santi M, Elli-
son DW, Tabori U, Hawkins C (2020) Integrated molecular and 
clinical analysis of 1000 pediatric low-grade gliomas. Cancer Cell 
37(569–583):e565. https ://doi.org/10.1016/j.ccell .2020.03.011
 14. Jones DT, Hutter B, Jager N, Korshunov A, Kool M, Warnatz 
HJ, Zichner T, Lambert SR, Ryzhova M, Quang DA, Fontebasso 
AM, Stutz AM, Hutter S, Zuckermann M, Sturm D, Gronych J, 
Lasitschka B, Schmidt S, Seker-Cin H, Witt H, Sultan M, Ral-
ser M, Northcott PA, Hovestadt V, Bender S, Pfaff E, Stark S, 
Faury D, Schwartzentruber J, Majewski J, Weber UD, Zapatka M, 
Raeder B, Schlesner M, Worth CL, Bartholomae CC, von Kalle 
C, Imbusch CD, Radomski S, Lawerenz C, van Sluis P, Koster J, 
Volckmann R, Versteeg R, Lehrach H, Monoranu C, Winkler B, 
Unterberg A, Herold-Mende C, Milde T, Kulozik AE, Ebinger 
M, Schuhmann MU, Cho YJ, Pomeroy SL, von Deimling A, Witt 
O, Taylor MD, Wolf S, Karajannis MA, Eberhart CG, Scheurlen 
W, Hasselblatt M, Ligon KL, Kieran MW, Korbel JO, Yaspo ML, 
Brors B, Felsberg J, Reifenberger G, Collins VP, Jabado N, Eils 
R, Lichter P, Pfister SM (2013) Recurrent somatic alterations of 
FGFR1 and NTRK2 in pilocytic astrocytoma. Nat Genet 45:927–
932. https ://doi.org/10.1038/ng.2682
 15. Selt F, Hohloch J, Hielscher T, Sahm F, Capper D, Korshunov A, 
Usta D, Brabetz S, Ridinger J, Ecker J, Oehme I, Gronych J, Mar-
quardt V, Pauck D, Bachli H, Stiles CD, von Deimling A, Remke 
M, Schuhmann MU, Pfister SM, Brummer T, Jones DT, Witt O, 
Milde T (2017) Establishment and application of a novel patient-
derived KIAA1549:BRAF-driven pediatric pilocytic astrocytoma 
model for preclinical drug testing. Oncotarget 8:11460–11479. 
https ://doi.org/10.18632 /oncot arget .14004 
 16. Usta D, Sigaud R, Buhl JL, Selt F, Marquardt V, Pauck D, Jansen 
J, Pusch S, Ecker J, Hielscher T, Vollmer J, Sommerkamp AC, 
Rubner T, Hargrave D, van Tilburg CM, Pfister SM, Jones DTW, 
Remke M, Brummer T, Witt O, Milde T (2020) A cell-based 
MAPK reporter assay reveals synergistic MAPK pathway activ-
ity suppression by MAPK inhibitor combination in BRAF-driven 
pediatric low-grade glioma cells. Mol Cancer Ther. https ://doi.
org/10.1158/1535-7163.MCT-19-1021
 17. Banerjee A, Jakacki RI, Onar-Thomas A, Wu SJ, Nicolaides T, 
Poussaint TY, Fangusaro J, Phillips J, Perry A, Turner D, Prados 
M, Packer RJ, Qaddoumi I, Gururangan S, Pollack IF, Goldman 
S, Doyle LA, Stewart CF, Boyett JM, Kun LE, Fouladi M (2017) 
A phase I trial of the MEK inhibitor selumetinib (AZD6244) in 
pediatric patients with recurrent or refractory low-grade glioma: 
a pediatric brain tumor consortium (PBTC) study. Neuro-Oncol 
19:1135–1144. https ://doi.org/10.1093/neuon c/now28 2
 18. Fangusaro J, Onar-Thomas A, Young Poussaint T, Wu S, Ligon 
AH, Lindeman N, Banerjee A, Packer RJ, Kilburn LB, Goldman 
S, Pollack IF, Qaddoumi I, Jakacki RI, Fisher PG, Dhall G, Baxter 
P, Kreissman SG, Stewart CF, Jones DTW, Pfister SM, Vezina 
G, Stern JS, Panigrahy A, Patay Z, Tamrazi B, Jones JY, Haque 
SS, Enterline DS, Cha S, Fisher MJ, Doyle LA, Smith M, Dun-
kel IJ, Fouladi M (2019) Selumetinib in paediatric patients with 
BRAF-aberrant or neurofibromatosis type 1-associated recurrent, 
refractory, or progressive low-grade glioma: a multicentre, phase 
2 trial. Lancet Oncolgy 20:1011–1022. https ://doi.org/10.1016/
S1470 -2045(19)30277 -3
 19. Dombi E, Baldwin A, Marcus LJ, Fisher MJ, Weiss B, Kim A, 
Whitcomb P, Martin S, Aschbacher-Smith LE, Rizvi TA, Wu J, 
Ershler R, Wolters P, Therrien J, Glod J, Belasco JB, Schorry E, 
Brofferio A, Starosta AJ, Gillespie A, Doyle AL, Ratner N, Wide-
mann BC (2016) Activity of selumetinib in neurofibromatosis type 
1-related plexiform neurofibromas. N Engl J Med 375:2550–2560. 
https ://doi.org/10.1056/NEJMo a1605 943
 20. Bouffet E, Kieran M, Hargrave D, Roberts S, Aerts I, Bronis-
cer A, Geoerger B, Dasgupta K, Tseng L, Russo M, Mookerjee 
B, Moertel C (2018) LGG-46. Trametinib therapy in pediatric 
patients with low-grade gliomas (LGG) with BRAF gene fusion; 
a disease-specific cohort in the first pediatric testing of trametinib. 
Neuro-Oncology 20:i114–i114. https ://doi.org/10.1093/neuon c/
noy05 9.387
 21. Kondyli M, Larouche V, Saint-Martin C, Ellezam B, Pouliot L, 
Sinnett D, Legault G, Crevier L, Weil A, Farmer JP, Jabado N, 
Perreault S (2018) Trametinib for progressive pediatric low-grade 
gliomas. J Neurooncol 140:435–444. https ://doi.org/10.1007/
s1106 0-018-2971-9
 22. Manoharan N, Choi J, Chordas C, Zimmerman MA, Scully J, 
Clymer J, Filbin M, Ullrich NJ, Bandopadhayay P, Chi SN, Yeo 
KK (2020) Trametinib for the treatment of recurrent/progressive 
pediatric low-grade glioma. J Neurooncol. https ://doi.org/10.1007/
s1106 0-020-03592 -8
 23. Miller C, Guillaume D, Dusenbery K, Clark HB, Moertel C (2017) 
Report of effective trametinib therapy in 2 children with progres-
sive hypothalamic optic pathway pilocytic astrocytoma: documen-
tation of volumetric response. J Neurosurg Pediatr 19:319–324. 
https ://doi.org/10.3171/2016.9.PEDS1 6328
 24. Paul MR, Pehlivan KC, Milburn M, Yeh-Nayre L, Elster J, Craw-
ford JR (2020) Trametinib-based treatment of pediatric CNS 
tumors: a single institutional experience. J Pediatr Hematol Oncol. 
https ://doi.org/10.1097/MPH.00000 00000 00181 9
 25. Perreault S, Larouche V, Tabori U, Hawkin C, Lippe S, Ellezam 
B, Decarie JC, Theoret Y, Metras ME, Sultan S, Cantin E, Routh-
ier ME, Caru M, Legault G, Bouffet E, Lafay-Cousin L, Hukin 
J, Erker C, Jabado N (2019) A phase 2 study of trametinib for 
patients with pediatric glioma or plexiform neurofibroma with 
refractory tumor and activation of the MAPK/ERK pathway: 
TRAM-01. BMC Cancer 19:1250. https ://doi.org/10.1186/s1288 
5-019-6442-2
 26. Capper D, Jones DTW, Sill M, Hovestadt V, Schrimpf D, Sturm D, 
Koelsche C, Sahm F, Chavez L, Reuss DE, Kratz A, Wefers AK, 
Huang K, Pajtler KW, Schweizer L, Stichel D, Olar A, Engel NW, 
Lindenberg K, Harter PN, Braczynski AK, Plate KH, Dohmen H, 
Garvalov BK, Coras R, Holsken A, Hewer E, Bewerunge-Hudler 
M, Schick M, Fischer R, Beschorner R, Schittenhelm J, Stasze-
wski O, Wani K, Varlet P, Pages M, Temming P, Lohmann D, 
Selt F, Witt H, Milde T, Witt O, Aronica E, Giangaspero F, Rush-
ing E, Scheurlen W, Geisenberger C, Rodriguez FJ, Becker A, 
Preusser M, Haberler C, Bjerkvig R, Cryan J, Farrell M, Deckert 
M, Hench J, Frank S, Serrano J, Kannan K, Tsirigos A, Bruck 
W, Hofer S, Brehmer S, Seiz-Rosenhagen M, Hanggi D, Hans V, 
Rozsnoki S, Hansford JR, Kohlhof P, Kristensen BW, Lechner 
M, Lopes B, Mawrin C, Ketter R, Kulozik A, Khatib Z, Heppner 
F, Koch A, Jouvet A, Keohane C, Muhleisen H, Mueller W, Pohl 
U, Prinz M, Benner A, Zapatka M, Gottardo NG, Driever PH, 
Kramm CM, Muller HL, Rutkowski S, von Hoff K, Fruhwald MC, 
Gnekow A, Fleischhack G, Tippelt S, Calaminus G, Monoranu 
CM, Perry A, Jones C, Jacques TS, Radlwimmer B, Gessi M, 
509Journal of Neuro-Oncology (2020) 149:499–510 
1 3
Pietsch T, Schramm J, Schackert G, Westphal M, Reifenberger 
G, Wesseling P, Weller M, Collins VP, Blumcke I, Bendszus M, 
Debus J, Huang A, Jabado N, Northcott PA, Paulus W, Gajjar A, 
Robinson GW, Taylor MD, Jaunmuktane Z, Ryzhova M, Plat-
ten M, Unterberg A, Wick W, Karajannis MA, Mittelbronn M, 
Acker T, Hartmann C, Aldape K, Schuller U, Buslei R, Lichter P, 
Kool M, Herold-Mende C, Ellison DW, Hasselblatt M, Snuderl 
M, Brandner S, Korshunov A, von Deimling A, Pfister SM (2018) 
DNA methylation-based classification of central nervous system 
tumours. Nature 555:469–474. https ://doi.org/10.1038/natur e2600 
0
 27. Sahm F, Schrimpf D, Jones DT, Meyer J, Kratz A, Reuss D, Cap-
per D, Koelsche C, Korshunov A, Wiestler B, Buchhalter I, Milde 
T, Selt F, Sturm D, Kool M, Hummel M, Bewerunge-Hudler M, 
Mawrin C, Schuller U, Jungk C, Wick A, Witt O, Platten M, Her-
old-Mende C, Unterberg A, Pfister SM, Wick W, von Deimling A 
(2016) Next-generation sequencing in routine brain tumor diag-
nostics enables an integrated diagnosis and identifies actionable 
targets. Acta Neuropathol 131:903–910. https ://doi.org/10.1007/
s0040 1-015-1519-8
 28. (2017) Common Terminology Criteria for Adverse Events 
(CTCAE), Version 5.0; 1.https ://ctep.cance r.gov/proto colde velop 
ment/elect ronic _appli catio ns/docs/CTCAE _v5_Quick _Refer 
ence_8.5x11.pdf
 29. Fangusaro J, Witt O, Hernaiz Driever P, Bag AK, de Blank P, 
Kadom N, Kilburn L, Lober RM, Robison NJ, Fisher MJ, Packer 
RJ, Young Poussaint T, Papusha L, Avula S, Brandes AA, Bouf-
fet E, Bowers D, Artemov A, Chintagumpala M, Zurakowski D, 
van den Bent M, Bison B, Yeom KW, Taal W, Warren KE (2020) 
Response assessment in paediatric low-grade glioma: recom-
mendations from the Response Assessment in Pediatric Neuro-
Oncology (RAPNO) working group. Lancet Oncol 21:e305–e316. 
https ://doi.org/10.1016/S1470 -2045(20)30064 -4
 30. Solomon J, Warren K, Dombi E, Patronas N, Widemann B (2004) 
Automated detection and volume measurement of plexiform 
neurofibromas in neurofibromatosis 1 using magnetic resonance 
imaging. Comput Med Imaging Graph 28:257–265. https ://doi.
org/10.1016/j.compm edima g.2004.03.002
 31. Knight T, Shatara M, Carvalho L, Altinok D, Poulik J, Wang ZJ 
(2019) Dramatic response to trametinib in a male child with neu-
rofibromatosis type 1 and refractory astrocytoma. Pediatr Blood 
Cancer. https ://doi.org/10.1002/pbc.27474 
 32. Goebel AM, Gnekow AK, Kandels D, Witt O, Schmidt R, Hernaiz 
Driever P (2019) Natural history of pediatric low-grade glioma 
disease-first multi-state model analysis. J Cancer 10:6314–6326. 
https ://doi.org/10.7150/jca.33463 
 33. Gross AM, Wolters PL, Dombi E, Baldwin A, Whitcomb P, Fisher 
MJ, Weiss B, Kim A, Bornhorst M, Shah AC, Martin S, Roderick 
MC, Pichard DC, Carbonell A, Paul SM, Therrien J, Kapustina 
O, Heisey K, Clapp DW, Zhang C, Peer CJ, Figg WD, Smith 
M, Glod J, Blakeley JO, Steinberg SM, Venzon DJ, Doyle LA, 
Widemann BC (2020) Selumetinib in children with inoperable 
plexiform neurofibromas. N Engl J Med 382:1430–1442. https ://
doi.org/10.1056/NEJMo a1912 735
 34. Hernaiz Diever P, von Hornstein S, Pietsch T, Kortmann R, War-
muth-Metz M, Emser A, Gnekow AK (2010) Natural history and 
management of low-grade glioma in NF-1 children. J Neurooncol 
100:199–207. https ://doi.org/10.1007/s1106 0-010-0159-zr
 35. Geoerger B, Moertel CL, Whitlock J, McCowage GB, Kieran MW, 
Broniscer A, Hargrave DR, Hingorani P, Kilburn LB, Mueller S, 
Tseng L, Nebot N, Dasgupta K, Russo MW, Fox E (2018) Phase 
1 trial of trametinib alone and in combination with dabrafenib 
in children and adolescents with relapsed solid tumors or neu-
rofibromatosis type 1 (NF1) progressive plexiform neurofibro-
mas (PN). J Clin Oncol 36:10537–10537. https ://doi.org/10.1200/
JCO.2018.36.15_suppl .10537 
 36. Gnekow AK, Walker DA, Kandels D, Picton S, Giorgio P, Grill 
J, Stokland T, Sandstrom PE, Warmuth-Metz M, Pietsch T, Gian-
gaspero F, Schmidt R, Faldum A, Kilmartin D, De Paoli A, De 
Salvo GL, of the Low Grade Glioma C, the participating c (2017) 
A European randomised controlled trial of the addition of etopo-
side to standard vincristine and carboplatin induction as part of 
an 18-month treatment programme for childhood (16 years) low 
grade glioma: a final report. Eur J Cancer 81:206–225. https ://doi.
org/10.1016/j.ejca.2017.04.019
 37. Buhl JL, Selt F, Hielscher T, Guiho R, Ecker J, Sahm F, Ridinger 
J, Riehl D, Usta D, Ismer B, Sommerkamp AC, Martinez-Barbera 
JP, Wefers AK, Remke M, Picard D, Pusch S, Gronych J, Oehme 
I, van Tilburg CM, Kool M, Kuhn D, Capper D, von Deimling 
A, Schuhmann MU, Herold-Mende C, Korshunov A, Brummer 
T, Pfister SM, Jones DTW, Witt O, Milde T (2019) The senes-
cence-associated secretory phenotype mediates oncogene-induced 
senescence in pediatric pilocytic astrocytoma. Clin Cancer Res 
25:1851–1866. https ://doi.org/10.1158/1078-0432.CCR-18-1965
 38. Poore B, Yuan M, Arnold A, Price A, Alt J, Rubens JA, Slusher 
BS, Eberhart CG, Raabe EH (2019) Inhibition of mTORC1 in 
pediatric low-grade glioma depletes glutathione and therapeuti-
cally synergizes with carboplatin. Neuro Oncol 21:252–263. https 
://doi.org/10.1093/neuon c/noy15 0
 39. van Tilburg CM, Selt F, Sahm F, Bachli H, Pfister SM, Witt O, 
Milde T (2018) Response in a child with a BRAF V600E mutated 
desmoplastic infantile astrocytoma upon retreatment with vemu-
rafenib. Pediatr Blood Cancer. https ://doi.org/10.1002/pbc.26893 
 40. Infante JR, Fecher LA, Falchook GS, Nallapareddy S, Gordon 
MS, Becerra C, DeMarini DJ, Cox DS, Xu Y, Morris SR, Ped-
dareddigari VG, Le NT, Hart L, Bendell JC, Eckhardt G, Kurzrock 
R, Flaherty K, Burris HA 3rd, Messersmith WA (2012) Safety, 
pharmacokinetic, pharmacodynamic, and efficacy data for the oral 
MEK inhibitor trametinib: a phase 1 dose-escalation trial. Lancet 
Oncol 13:773–781. https ://doi.org/10.1016/S1470 -2045(12)70270 
-X
Publisher’s Note Springer Nature remains neutral with regard to 
jurisdictional claims in published maps and institutional affiliations.
510 Journal of Neuro-Oncology (2020) 149:499–510
1 3
Affiliations
Florian Selt1,2,3  · Cornelis M. van Tilburg1,2,3 · Brigitte Bison4 · Philipp Sievers5,6 · Inga Harting7 · Jonas Ecker1,2,3 · 
Kristian W. Pajtler1,3,14 · Felix Sahm1,5,6 · Annabelle Bahr8 · Michèle Simon8 · David T. W. Jones1,15 · Lennart Well9 · 
Victor‑Felix Mautner10 · David Capper11,12 · Pablo Hernáiz Driever8 · Astrid Gnekow13 · Stefan M. Pfister1,3,14 · 
Olaf Witt1,2,3 · Till Milde1,2,3
1 Hopp Children’s Cancer Center (KiTZ), Im Neuenheimer 
Feld 430, 69120 Heidelberg, Germany
2 Clinical Cooperation Unit Pediatric Oncology, German 
Cancer Research Center (DKFZ) and German Consortium 
for Translational Cancer Research (DKTK), Heidelberg, 
Germany
3 KiTZ Clinical Trial Unit (ZIPO), Department of Pediatric 
Hematology and Oncology, Heidelberg University Hospital, 
Heidelberg, Germany
4 Institute of Diagnostic and Interventional Neuroradiology, 
University Hospital Wuerzburg, Würzburg, Germany
5 Department of Neuropathology, Institute of Pathology, 
Heidelberg University Hospital, Heidelberg, Germany
6 Clinical Cooperation Unit Neuropathology, German 
Consortium for Translational Cancer Research (DKTK), 
German Cancer Research Center (DKFZ), Heidelberg, 
Germany
7 Department of Neuroradiology, Heidelberg University 
Hospital, Heidelberg, Germany
8 Department of Pediatric Oncology/Hematology, Charité 
Universitaetsmedizin Berlin, Corporate Member of Freie 
Universitaet Berlin, Humboldt-Universitaet zu Berlin 
and Berlin Institute of Health, Berlin, Germany
9 Department of Diagnostic and Interventional Radiology 
and Nuclear Medicine, University Medical Center 
Hamburg-Eppendorf, Hamburg, Germany
10 Department of Neurology, University Medical Center 
Hamburg-Eppendorf, Hamburg, Germany
11 Department of Neuropathology, Corporate Member of Freie 
Universitaet Berlin, Humboldt-Universitaet Zu Berlin, 
and Berlin Institute of Health, Charité-Universitaetsmedizin 
Berlin, Berlin, Germany
12 German Cancer Consortium (DKTK), German Cancer 
Research Center (DKFZ), Partner Site Berlin, Berlin, 
Germany
13 Swabian Children’s Cancer Center, University Hospital 
Augsburg, Augsburg, Germany
14 Division of Pediatric Neurooncology, German Cancer 
Research Center (DKFZ) and German Consortium 
for Translational Cancer Research (DKTK), Heidelberg, 
Germany
15 Pediatric Glioma Research Group, German Cancer Research 
Center (DKFZ), Heidelberg, Germany
